PASSAGE BIO INC (PASG)
US7027121000 - Common Stock
Which stocks are moving on Friday?
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Let's take a look at the stocks that are in motion in today's session.
These stocks are moving in today's session
Curious about the stocks that are showing activity after the closing bell on Thursday?
Which stocks are moving after the closing bell on Thursday?
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data...
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the...
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) ...
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the...
Passage Bio Welcomes Tom Kassberg to Board of Directors
Passage Bio Welcomes Tom Kassberg to Board of Directors
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the...
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the...
PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the second quarter of 2024.
PASG Stock Earnings: Passage Bio Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Passage Bio (NASDAQ:PASG) just reported results for the second quarter of 2024....
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights
Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with...
Passage Bio to Participate in Upcoming Investor Conferences
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!
Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients
Agency feedback from Type C meeting process supports the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD...
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
Passage Bio to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PHILADELPHIA, June 05, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the...
Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship Award
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the...
PASG Stock Earnings: Passage Bio Beats EPS for Q1 2024
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the first quarter of 2024.
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Passage Bio Reports First Quarter 2024 Financial Results and Provides Recent Business Highlights
Updated interim data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 PBFT02 achieved consistent elevation of CSF progranulin at six months...
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
PHILADELPHIA, April 22, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the...
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
PASG stock results show that Passage Bio beat analyst estimates for earnings per share the fourth quarter of 2023.
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Passage Bio (NASDAQ:PASG) just reported results for the fourth quarter of 2023....
Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
$10,000 scholarship to be awarded to a rising junior with a life science major attending a Pennsylvania-based four-year college or university Scholarship...
Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights
Continued momentum in upliFT-D trial of PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin mutations (GRN) with clinical...